14.45
-0.02 (-0.14%)
| Previous Close | 14.47 |
| Open | 14.59 |
| Volume | 2,028,495 |
| Avg. Volume (3M) | 1,816,922 |
| Market Cap | 2,333,328,128 |
| Price / Earnings (Forward) | 31.25 |
| Price / Sales | 5.89 |
| Price / Book | 2.16 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 |
| Profit Margin | -3.13% |
| Operating Margin (TTM) | 14.40% |
| Diluted EPS (TTM) | -0.080 |
| Quarterly Revenue Growth (YOY) | 14.00% |
| Total Debt/Equity (MRQ) | 29.46% |
| Current Ratio (MRQ) | 2.13 |
| Operating Cash Flow (TTM) | 80.47 M |
| Levered Free Cash Flow (TTM) | 67.68 M |
| Return on Assets (TTM) | 0.75% |
| Return on Equity (TTM) | -1.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Certara, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 2.32% |
| % Held by Institutions | 96.93% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Teacher Retirement System Of Texas | 31 Dec 2024 | 4,557,951 |
| Brown Brothers Harriman & Co | 31 Dec 2024 | 3,818,613 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Keybanc, 24.57%) | Buy |
| Median | 15.00 (3.81%) | |
| Low | 11.00 (Barclays, -23.88%) | Hold |
| Average | 14.75 (2.08%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 12.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Keybanc | 16 Apr 2025 | 18.00 (24.57%) | Buy | 13.53 |
| Baird | 11 Apr 2025 | 13.00 (-10.03%) | Hold | 12.91 |
| Barclays | 10 Apr 2025 | 11.00 (-23.88%) | Hold | 10.51 |
| 28 Feb 2025 | 13.00 (-10.03%) | Hold | 11.98 | |
| Stephens & Co. | 27 Feb 2025 | 17.00 (17.65%) | Buy | 12.40 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Apr 2025 | Announcement | Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing |
| 14 Apr 2025 | Announcement | Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization |
| 01 Apr 2025 | Announcement | Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities |
| 05 Mar 2025 | Announcement | Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions |
| 26 Feb 2025 | Announcement | Certara Reports Fourth Quarter 2024 Financial Results |
| 29 Jan 2025 | Announcement | Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |